Lilly, Zepbound and LifeMD

Teladoc, LifeMD tie up with Lilly's pharmacy partner to offer Zepbound
(Reuters) -Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement with Gifthealth, the pharmacy partner of Eli Lilly's direct-to-consumer site, LillyDirect, to offer patients the weight-loss drug,
LifeMD Integrates With LillyDirect to Offer Access of Single-dose Vials of Zepbound
LifeMD, a virtual primary care services provider, said it is integrating with Gifthealth which will make Lilly's single-dose vials of Zepbound accessible to the company's eligible patients.
LifeMD® Announces Integration with LillyDirect Pharmacy Provider to Offer Patients Streamlined Access to Branded Dual GLP-1/GIP Zepbound
(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced it is integrating with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of Lilly’s prescription obesity treatment Zepbound ® (tirzepatide) to eligible LifeMD patients.
Two telehealth firms turn to branded Zepbound as restrictions loom on copies
Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer website LillyDirect pharmacy partner, Gifthealth, to offer patients the weight-loss drug,
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
LifeMD announces integration with LillyDirect pharmacy provider
LifeMD (LFMD) announced it is integrating with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of ...
LifeMD, Inc. (LFMD): A Bull Case Theory
We came across a bullish thesis on LifeMD, Inc. (LFMD) on Twitter by Cluseau Investments. In this article, we will summarize ...
LifeMD Inc (LFMD) Q4 2024: Everything You Need to Know Ahead of Earnings
LifeMD Inc (NASDAQ:LFMD) is set to release its Q4 2024 earnings on March 10, 2025. The consensus estimate for Q4 2024 revenue ...
Lake Street Sticks to Its Buy Rating for LifeMD (LFMD)
In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on LifeMD (LFMD – Research Report), with a price target of ...